

# Gianpiero Fasola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2995790/publications.pdf>

Version: 2024-02-01

135  
papers

3,059  
citations

186265

28  
h-index

189892

50  
g-index

137  
all docs

137  
docs citations

137  
times ranked

5128  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave. PLoS ONE, 2022, 17, e0262784.	2.5	2
2	Immunotherapy in NSCLC Patients with Brain Metastases. International Journal of Molecular Sciences, 2022, 23, 7068.	4.1	12
3	Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic. Oncologist, 2021, 26, e694-e703.	3.7	3
4	The impact of COVID-19 pandemic on oncology workload: The experience of an Italian Reference Cancer Center.. Journal of Clinical Oncology, 2021, 39, e13520-e13520.	1.6	1
5	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. European Journal of Cancer, 2021, 148, 112-116.	2.8	7
6	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.	2.2	14
7	Impact of innovation in oncology: more questions than answers. Tumori, 2021, 107, 478-482.	1.1	3
8	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	3.7	5
9	Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy. Journal of Cancer Policy, 2021, 29, 100297.	1.4	6
10	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer, 2020, 140, 59-64.	2.0	33
11	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva. International Journal of Gynecological Cancer, 2020, 30, 1672-1677.	2.5	17
12	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 2020, 16, 2645-2660.	2.4	1
13	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs and Aging, 2020, 37, 677-689.	2.7	1
14	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. Oncologist, 2020, 25, 661-668.	3.7	21
15	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 2020, 11, 1268-1273.	1.0	6
16	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	2.4	2
17	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	3.3	18
18	Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , 2019, 134, 121-126.	2.0	4
20	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019, 11, 1243.	3.7	40
21	Comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos". <i>Lung Cancer</i> , 2019, 136, 150.	2.0	2
22	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	3.7	7
23	Emerging therapies in malignant pleural mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102815.	4.4	17
24	The <sc>IMPACT</sc> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	7.3	61
25	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. <i>British Journal of Cancer</i> , 2019, 120, 522-526.	6.4	11
26	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	3.2	25
27	Prognostic role of disease extent and lymphocyte"monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019, 29, 510-515.	1.2	12
28	Prognostic evaluation in palliative care: final results from a prospective cohort study. <i>Supportive Care in Cancer</i> , 2019, 27, 2095-2102.	2.2	20
29	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. <i>Annals of Translational Medicine</i> , 2019, 7, 14-14.	1.7	11
30	INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 3-9.	0.5	5
31	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470.	2.3	18
32	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018, 14, 849-859.	2.4	14
33	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2018, 14, 699-707.	2.4	29
34	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 205-213.	2.4	8
35	ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2018, 124, 4667-4675.	4.1	12
36	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. <i>International Journal of Epidemiology</i> , 2018, 47, 1981-1991.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. <i>Melanoma Research</i> , 2018, 28, 547-554.	1.2	8
38	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
39	Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2029-2047.	2.5	9
40	Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells. <i>Cancers</i> , 2018, 10, 270.	3.7	15
41	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 140, 559-568.	2.9	9
42	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13079-e13079.	1.6	2
43	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24014-e24014.	1.6	1
44	Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18865-e18865.	1.6	0
45	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12039-12039.	1.6	0
46	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 783-791.	2.5	36
47	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1179-1190.	2.2	96
48	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	3.1	33
49	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017, 31, 114-120.	2.2	49
50	Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. <i>Future Oncology</i> , 2017, 13, 135-144.	2.4	9
51	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. <i>Current Drug Targets</i> , 2017, 18, 341-362.	2.1	8
52	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 194.	2.0	46
53	Setting and timing of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21502-e21502.	1.6	0
54	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12010-e12010.	1.6	0

#	ARTICLE	IF	CITATIONS
55	A novel MGMT methylation-based prognostic score in patients with glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2048-2048.	1.6	0
56	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€”Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	1.6	0
57	Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example. OncoTargets and Therapy, 2016, Volume 9, 5399-5404.	2.0	1
58	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
59	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (VICTORIA-BIL study). Cancer, 2016, 122, 574-581.	4.1	121
60	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	6.4	56
61	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. Clinical Colorectal Cancer, 2016, 15, 7-15.	2.3	3
62	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
63	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. Journal of Clinical Oncology, 2016, 34, 342-342.	1.6	0
64	Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.. Journal of Clinical Oncology, 2016, 34, e21601-e21601.	1.6	0
65	Anxiety, depression in lung cancer and the predictive role of unmet needs: Data from a national multicenter study (E-LUNG).. Journal of Clinical Oncology, 2016, 34, 10062-10062.	1.6	0
66	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. Journal of Clinical Oncology, 2016, 34, 1554-1554.	1.6	0
67	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1458-1467.	1.1	50
68	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	1.8	14
69	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	2.0	5
70	Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution. Journal of Clinical Oncology, 2015, 33, 3841-3842.	1.6	4
71	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Critical Reviews in Oncology/Hematology, 2015, 95, 165-178.	4.4	26
72	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Oncologist, 2015, 20, 719-724.	3.7	46

#	ARTICLE	IF	CITATIONS
73	MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. <i>Future Oncology</i> , 2015, 11, 1201-1209.	2.4	15
74	Prognostic role of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutations in advanced colorectal cancer. <i>Future Oncology</i> , 2015, 11, 629-640.	2.4	49
75	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	4.1	4
76	A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study. <i>Journal of Clinical Oncology</i> , 2015, 33, 281-281.	1.6	2
77	First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST. <i>Journal of Clinical Oncology</i> , 2015, 33, 660-660.	1.6	9
78	Prognostic characterization in the terminal phase of cancer: May clinical prediction be improved?. <i>Journal of Clinical Oncology</i> , 2015, 33, e20507-e20507.	1.6	0
79	Endocrine maintenance therapy in luminal breast cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e11578-e11578.	1.6	0
80	Treatment during the last month of life in advanced cancer patients. <i>Journal of Clinical Oncology</i> , 2015, 33, e17649-e17649.	1.6	0
81	Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) + either panitumumab (pmab) or bevacizumab (bev). <i>Journal of Clinical Oncology</i> , 2015, 33, 3535-3535.	1.6	5
82	Endocrine therapy and chemotherapy in luminal metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e11573-e11573.	1.6	0
83	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. <i>Anticancer Research</i> , 2015, 35, 2391-9.	1.1	1
84	Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?. <i>OncoTargets and Therapy</i> , 2014, 7, 1783.	2.0	14
85	Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. <i>Oncologist</i> , 2014, 19, 608-615.	3.7	205
86	Factors affecting patient's perception of anticancer treatments side-effects: an observational study. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 139-150.	2.4	26
87	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 733-737.	1.1	28
88	Drug waste minimization as an effective strategy of cost-containment in Oncology. <i>BMC Health Services Research</i> , 2014, 14, 57.	2.2	58
89	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2240-2247.	1.6	573
90	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	4.1	32

#	ARTICLE	IF	CITATIONS
91	Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. <i>Supportive Care in Cancer</i> , 2014, 22, 2527-2533.	2.2	16
92	Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3629-3629.	1.6	5
93	Clinical advances in the development of novel VEGFR2 inhibitors. <i>Annals of Translational Medicine</i> , 2014, 2, 123.	1.7	121
94	Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts): A retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 511-511.	1.6	1
95	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. <i>Journal of Clinical Oncology</i> , 2014, 32, e22006-e22006.	1.6	0
96	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, e11524-e11524.	1.6	0
97	Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems. <i>BMC Health Services Research</i> , 2013, 13, 522.	2.2	34
98	Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. <i>Tumor Biology</i> , 2013, 34, 131-137.	1.8	49
99	Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 32-44.	4.4	14
100	HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2370-2387.	4.1	14
101	Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. <i>Melanoma Research</i> , 2013, 23, 96-101.	1.2	13
102	PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 446-446.	1.6	13
103	Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage?. <i>World Journal of Gastroenterology</i> , 2013, 19, 2131.	3.3	5
104	Cancer of unknown primary origin: a case report. <i>Clinical Management Issues</i> , 2013, 7, 27-34.	0.3	0
105	A Model to Estimate Human Resource Needs for the Treatment of Outpatients With Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, 13-17.	2.5	13
106	Adopting Integrated Care Pathways in Non-Small-Cell Lung Cancer: From Theory to Practice. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1283-1290.	1.1	21
107	Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. <i>Anti-Cancer Drugs</i> , 2012, 23, 326-334.	1.4	14
108	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13070-e13070.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, e13058-e13058.	1.6	0
110	Association of body mass index and outcome in advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 1044-1044.	1.6	0
111	Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)?. Journal of Clinical Oncology, 2012, 30, 3612-3612.	1.6	0
112	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM) Tj ETQq0 0 0 rg28 /Overlock 10 Tf 50	1.6	0
113	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). Journal of Thoracic Oncology, 2010, 5, 1354-1360.	1.1	24
114	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. Oncologist, 2009, 14, 497-510.	3.7	64
115	Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. Journal of Cancer Research and Clinical Oncology, 2009, 135, 451-457.	2.5	42
116	Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anti-Cancer Drugs, 2009, 20, 503-507.	1.4	29
117	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2008, 68, 183-196.	4.4	33
118	Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study. BMC Health Services Research, 2008, 8, 70.	2.2	54
119	Anticancer drugs and central nervous system: Clinical issues for patients and physicians. Cancer Letters, 2008, 267, 1-9.	7.2	11
120	Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 331-342.	2.4	19
121	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial- An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist, 2007, 12, 1215-1224.	3.7	82
122	Bone Scan for Baseline Staging in Invasive Breast Cancer at the Time of Primary Presentation. Breast Care, 2007, 2, 358-364.	1.4	6
123	Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Research and Treatment, 2007, 105, 133-138.	2.5	14
124	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer, 2006, 52, 89-92.	2.0	12
125	Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report. BMC Cancer, 2006, 6, 289.	2.6	14
126	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 2004, 46, 99-106.	2.0	11



#	ARTICLE	IF	CITATIONS
127	Infections in Patients with Acute Non-Lymphocytic Leukemia Nursed with Central or Peripheral Venous Access. <i>Tumori</i> , 1993, 79, 112-115.	1.1	2
128	Effectiveness and Toxicity of «Beld» Polychemotherapy in Advanced Malignant Melanoma. <i>Tumori</i> , 1989, 75, 229-232.	1.1	3
129	Maintenance treatment of multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 145-151.	2.2	3
130	A Phase II Study of Mitoxantrone. <i>Tumori</i> , 1988, 74, 579-583.	1.1	1
131	In vitro exposure of leukemic cells to low concentration arabinosyl cytosine: No evidence of differentiation inducing activity. <i>Blut</i> , 1987, 54, 299-306.	1.2	0
132	Cell kinetic effect of low dose arabinosyl cytosine. <i>British Journal of Haematology</i> , 1987, 67, 33-37.	2.5	6
133	Relationship of serum lactate dehydrogenase level with first remission length in adult acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1987, 66, 49-53.	2.5	8
134	Serum LDH Concentration in Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 1984, 72, 231-238.	1.4	35
135	Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1